BIOXCEL THERAPEUTICS INC's ticker is BTAI and the CUSIP is 09075P105. A total of 109 filers reported holding BIOXCEL THERAPEUTICS INC in Q2 2021. The put-call ratio across all filers is 1.62 and the average weighting 0.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $45,623 | -51.3% | 18,033 | +28.1% | 0.00% | – |
| Q2 2023 | $93,720 | +15114.3% | 14,072 | +42542.4% | 0.00% | – |
| Q1 2023 | $616 | -13.1% | 33 | 0.0% | 0.00% | – |
| Q4 2022 | $709 | -85.8% | 33 | -92.0% | 0.00% | – |
| Q3 2022 | $5,000 | -37.5% | 415 | -32.1% | 0.00% | – |
| Q2 2022 | $8,000 | -46.7% | 611 | -14.8% | 0.00% | – |
| Q1 2022 | $15,000 | -11.8% | 717 | -13.3% | 0.00% | – |
| Q4 2021 | $17,000 | -46.9% | 827 | -21.2% | 0.00% | – |
| Q3 2021 | $32,000 | -22.0% | 1,050 | -24.9% | 0.00% | – |
| Q2 2021 | $41,000 | -80.7% | 1,398 | -71.6% | 0.00% | – |
| Q1 2021 | $212,000 | -10.9% | 4,916 | -4.7% | 0.00% | -100.0% |
| Q4 2020 | $238,000 | +15.0% | 5,161 | +7.8% | 0.00% | 0.0% |
| Q3 2020 | $207,000 | +66.9% | 4,789 | +105.0% | 0.00% | – |
| Q2 2020 | $124,000 | +82.4% | 2,336 | -22.9% | 0.00% | – |
| Q1 2020 | $68,000 | – | 3,028 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Logos Global Management LP | 550,000 | $23,848,000 | 3.05% |
| SPHERA FUNDS MANAGEMENT LTD. | 269,300 | $11,677,000 | 1.15% |
| Avidity Partners Management LP | 538,000 | $23,328,000 | 1.08% |
| Knoll Capital Management, LLC | 20,000 | $867,000 | 0.71% |
| Maven Securities LTD | 200,000 | $8,610,000 | 0.71% |
| Prosight Management, LP | 29,800 | $1,292,000 | 0.62% |
| Artemis Investment Management LLP | 1,001,708 | $43,383,000 | 0.54% |
| Ikarian Capital, LLC | 150,000 | $6,504,000 | 0.47% |
| AlphaCentric Advisors LLC | 20,000 | $867,000 | 0.42% |
| MOODY ALDRICH PARTNERS LLC | 19,872 | $862,000 | 0.18% |